Insulin Delivery Devices Market Outlook To 2024: Key Product Categories (Insulin Syringes, Pens, Pumps, Injectors), End-Use (Hospitals, Home Healthcare), Regional Segmentation, Competitive Dynamics, M&A Insights, Pricing Analysis (OPP, IPP, RAP), And Segment Forecast

$3,650.00$6,650.00

Clear
  • Report Description
  • Table of Content
  • Highlight
  • Research Methodology
  • Request Free Sample

The global insulin delivery devices market was valued at $10.4 bn in 2016 and is anticipated to reach over $18.3bn by 2024.

 

The insulin delivery devices market is anticipated to witness lucrative growth owing to the rise in prevalence of obesity, diabetes, growing geriatric population and changes in lifestyle. The lifestyle factors such as lack of physical activity, smoking, substance abuse, alcohol, and constant stress are strongly contributing to the early onset of diabetes and thus patients are now using diabetic management products for a significantly longer period.

 

The WHO (World Health Organization) estimates that in 2014, nearly 1.9 billion (39% of adults) aged 18 years and above were overweight, and out of these, 600 million (13% adults) were obese. The International Diabetes Federation (IDF), estimates that in 2015, over 400 million adults had diabetes and by 2040, it is estimated that over 642 million adults will be impacted due to the disease. The geographical and demographic shift in the prevalence of diabetes is evident as 75% of adults with diabetes are present in low-income, middle-income countries. The significant rise in prevalence of diabetes and obesity is anticipated to propel the usage of various insulin delivery devices over the forecast period.

 

The rise in geriatric population is amongst the key factors propelling the demand for insulin delivery devices. The IDF data suggest that majority of the diabetic population is in the age group of 40 years to 59 years. Moreover, 46% of the people with diabetes are undiagnosed and in 2015, and nearly 5 million deaths are attributed to the condition. In the U.S., as per the Administration of Aging (AoA) estimates, there are over 46.2 million people aged 65 and above and by 2040, this population is expected to increase by 21.7%. The significant rise in the aging population is anticipated to reinforce growth over the next few years strongly.

 

Insulin Delivery Devices Market 2024

 

Pricing Analysis

 

“Optimal Price Point (OPP) for Products”

 

Estimated Average insulin delivery device cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model. The average cost of insulin pumps is in the range of USD 4500 to USD 6000, and therefore are unaffordable to a large section of the population in living in the low and middle-income countries. The insulin pens are available in the price range of USD 300 to USD 700, whereas the other products are available at a much lower cost. Moreover, the technological advancements and rise in diabetic population, growing healthcare expenditure are improving access to quality healthcare and drive the market growth over the forecast period.

 

Insulin Delivery Devices Market by “Product”

 

The key products analyzed in the study include insulin pumps, syringes, needles, and injections. In 2016, insulin pens accounted for the largest share of over 39% owing to their wide usage portability, and convenience for use at any external location away from home. Some of the notable insulin products include Apidra, Victoza, Humalog, NovoLog, NovoPen, Autopen and others. Due to the rise in disease prevalence and healthcare expenditure, the demand for insulin products is expected to witness significant growth over the next few years. Moreover, the growing use of insulin injections and syringes is expected to create a niche market with low pricing and high volumes.

 

 

Insulin Delivery Devices Market by “End-Use”

 

Based on end-use, the market is segmented as hospitals, home healthcare and others. The home healthcare contributed the maximum revenue in 2016 and is expected to continue its lead over the forecast period. The growing awareness about diabetes management in home care settings using the portable injections, pumps, pens and other products is a key factor driving the market growth. Moreover, the significant cost and time saved by avoiding hospital visits are encouraging more patients to opt for home care treatment.

 

Europe Insulin Deliver Devices Market

 

Regional Segmentation

 

In 2016, North America was the leading region with a market share of nearly 39.5%, due to the high disease burden, presence of robust reimbursement framework, rising awareness about technologically advanced products, and patient safety features. The high healthcare expenditure in the U.S., the presence of global R&D headquarters, and streamlined clinical trial and product approval process of the U.S. FDA enables the introduction of several new products and technologies each year are some of the additional factors contributing to the high share of the region.

 

Asia Pacific is anticipated to register the highest CAGR of over 8.4% through the forecast period. The countries such as India and China now have the maximum number of people with obesity, lifestyle disorders, and diabetes. The IDF data suggests that the six South East Asian nations including India, Bangladesh, Nepal, Sri Lanka, Maldives and Mauritius collectively account for 78 million patients. Moreover, India is the diabetic capital of the world with 69.2 million patients living with diabetes. The high unmet needs, rising healthcare expenditure to improve healthcare access, awareness about genetic factors, lifestyle factors, physical health, and other nutritional factors is anticipated to propel market growth over the next few years.

.

“Competitive Landscape” and “Merger & Acquisition Insights”

 

The insulin delivery devices market is dominated by players such as Novo Nordisk A/S, Eli Lilly, Becton, Dickinson and Company; Medtronic, Abbott, F. Hoffmann-La Roche Ltd, Mylan, Biocon and others. The market is highly competitive and companies are looking out to acquire suitable assets and extend their dominance. Moreover, the high R&D investment for diabetes management is driving innovation and use of modern technology. For instance, the development of wearable insulin pump patch is anticipated to generate significant revenue over the next few years.

 

Market Segmentation

 

Insulin Delivery Devices Market by Product (Revenue, Million, 2014 – 2024)

  • Insulin Syringes
  • Insulin Pens
  • Insulin Pumps
  • Insulin Injectors

Insulin Delivery Devices Market by End-Use, (Revenue, USD Million, 2014 – 2024)

  • Hospitals
  • Homecare
  • Others

Insulin Delivery Devices Market Regional Outlook (Revenue, USD Million, 20124- 2024)

North America

  • U.S.
  • Canada

Europe

  • UK
  • Germany
  • France
  • Italy
  • Spain

Asia Pacific

  • Japan
  • China
  • India

Latin America

  • Brazil
  • Mexico
  • Columbia

Middle East and Africa

  • South Africa
  • Saudi Arabia

Chapter 1 Methodology and Scope

  • Research Methodology
  • Research Scope & Assumptions
  • List of Data Sources

Chapter 2 Executive Summary

Chapter 3 Insulin Delivery Devices Market Overview

  • Global Disease Landscape
  • Global Healthcare Expenditure

Chapter 4 Insulin Delivery Devices Market Industry Outlook

  • Market Overview
  • Market Segmentation
  • Market Size and Growth Prospects
  • Leading Brand Dynamics
  • Key Market Drivers
    • Rising Prevalence of Diabetes
    • Increasing Geriatric Population
    • Growing Investment for Research and Development
  • Key Market Challenges
    • High Cost of Insulin Delivery Devices
    • Shortage of Trained Professionals
  • Key Opportunities Prioritized
  • Industry Analysis - Porter’s
  • Insulin Delivery Devices Market-PESTEL Analysis

Chapter 5: - Insulin Delivery Devices Market by “Product” (USD Million)

Insulin Delivery Devices Market Landscape by Product Type- 2016 & 2024
  • Insulin Syringes
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Insulin Pens
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Insulin Pumps
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Insulin Injectors
    • Market Landscape Analysis, 2016-2024 (USD Mn)

Chapter 6: - Insulin Delivery Devices Market by “End-Use” (USD Million)

Insulin Delivery Devices Market Landscape by Technology Type- 2016 & 2024
  • Hospital
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Home Healthcare
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Others
    • Market Landscape Analysis, 2016-2024 (USD Mn)

Chapter 7: Regional Market Outlook

Insulin Delivery Devices Market Landscape by Region- 2016
  • North America Market Landscape Analysis, 2016-2024 (USD Mn)
    • U.S. Market Landscape Analysis, 2016-2024
    • Canada Market Landscape Analysis-2016-2024
  • Europe Market Landscape Analysis, 2016-2024 (USD Mn)
    • UK Market Landscape Analysis, 2016-2024
    • Germany Market Landscape Analysis, 2016-2024
    • France Market Landscape Analysis, 2016-2024
    • Italy Market Landscape Analysis, 2016-2024
    • Spain Market Landscape Analysis, 2016-2024
  • Latin America Market Landscape Analysis, 2016-2024 (USD Mn)
    • Brazil Market Landscape Analysis, 2016-2024
    • Mexico Market Landscape Analysis, 2016-2024
    • Colombia Market Landscape Analysis, 2016-2024
  • Asia pacific Market Landscape Analysis, 2016-2024 (USD Mn)
    • Japan Market Landscape Analysis, 2016-2024
    • China Market Landscape Analysis, 2016-2024
    • India Market Landscape Analysis, 2016-2024
  • Middle East & Africa Market Landscape Analysis, 2014-2024 (USD Mn)
    • Saudi Arabia Market Landscape Analysis, 2014-2024
    • South Africa Market Landscape Analysis, 2014-2024

Chapter 8: Pricing Analysis

  Optimal Price Points (OPP), Indifference price points (IPP) and Range of Acceptable Prices and (RAP) of leading brands by Region- 2016
  • North America Pricing Analysis (OPP, IPP, and RAP - 2016)
    • U.S. Pricing Analysis-2016
    • Canada Pricing Analysis-2016
  • Europe Pricing Analysis (OPP, IPP, and RAP - 2016)
    • UK Pricing Analysis-2016
    • Germany Pricing Analysis-2016
    • France Pricing Analysis-2016
    • Italy Pricing Analysis-2016
    • Spain Pricing Analysis-2016
  • Latin America Pricing Analysis (OPP, IPP, and RAP - 2016)
    • Brazil Pricing Analysis-2016
    • Mexico Pricing Analysis-2016
    • Colombia Pricing Analysis-2016
  • Asia Pacific Pricing Analysis (OPP, IPP, and RAP - 2016)
    • Japan Pricing Analysis-2016
    • China Pricing Analysis-2016
    • India Pricing Analysis-2016
  • Middle East Pricing Analysis (OPP, IPP, and RAP - 2016)
    • Saudi Arabia Pricing Analysis-2016
    • South Africa Pricing Analysis-2016

Chapter 9: Insulin Delivery Devices Pipeline Analysis

  • Executive Summary
  • Late Stage Pipeline analysis
  • Key R&D trends

Chapter 10: Insulin Delivery Devices Merger &Acquisition Outlook

  • Factors driving M&A in smart syringes market
  • Key trends and future outlook

Chapter 11: Insulin Delivery Devices Regulatory & Patent Outlook

  • Regulatory Landscape by Region (U.S., Europe, and RoW)
  • Patent Landscape by Region (U.S., Europe, and RoW)

Chapter 12: Competitive Landscape

  • Eli Lilly and Company 
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Novo Nordisk A/S
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Sanofi
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Hoffmann-La Roche, Ltd.
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Abbott Laboratories
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Biocon Ltd.
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Ypsomed AG
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Medtronic
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Wockhardt Ltd.
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Siemens AG
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  List of Tables  
  • TABLE 1 Insulin Delivery Devices Market - Industry Snapshot & Key Buying Criteria, 2014 - 2024
  • TABLE 2 Global Insulin Delivery Devices Market, 2014 – 2024
  • TABLE 3 Global Insulin Delivery Devices Market Analysis by Product-2016
  • TABLE 4 Global Insulin Delivery Devices Market Analysis by Technology -2016
  • TABLE 5 Global Insulin Delivery Devices Market Analysis by Application-2016
  • TABLE 7 Global Insulin Delivery Devices Market Analysis by Geography-2016
  • TABLE 8 Global Insulin Delivery Devices Market Analysis by Leading Brands-2016
  • TABLE 9 Insulin Delivery Devices Market - Key market driver analysis
  • TABLE 10 Insulin Delivery Devices Market - Key market restraint analysis
  • TABLE 11 North America Market Insulin Delivery Devices Landscape Analysis, 2016-2024 (USD Mn)
  • TABLE 12U.S. Insulin Delivery Devices Market Landscape Analysis, 2016-2024
  • TABLE 13 Canada Insulin Delivery Devices Market Landscape Analysis, 2016-2024
  • TABLE 14 Europe Insulin Delivery Devices Market Landscape Analysis, 2016-2024 (USD Mn)
  • TABLE 15 U.K Insulin Delivery Devices Market Landscape Analysis, 2016-2024
  • TABLE 16 Germany Insulin Delivery Devices Market Landscape Analysis, 2016-2024
  • TABLE 17 France Insulin Delivery Devices Market Landscape Analysis, 2016-2024
  • TABLE 18 Italy Insulin Delivery Devices Market Landscape Analysis, 2016-2024
  • TABLE 19 Spain Insulin Delivery Devices Market Landscape Analysis, 2016-2024
  • TABLE 20 Latin America Insulin Delivery Devices Market Landscape Analysis, 2016-2024 (USD Mn)
  • TABLE 21 Brazil Insulin Delivery Devices Market Landscape Analysis, 2016-2024
  • TABLE 22 Mexico Insulin Delivery Devices Market Landscape Analysis, 2016-2024
  • TABLE 20 Colombia Insulin Delivery Devices Market Landscape Analysis, 2016-2024
  • TABLE 21 Asia pacific Insulin Delivery Devices Market Landscape Analysis, 2016-2024 (USD Mn)
  • TABLE 22 Japan Insulin Delivery Devices Market Landscape Analysis, 2016-2024
  • TABLE 23 China Insulin Delivery Devices Market Landscape Analysis, 2016-2024
  • TABLE 24 India Insulin Delivery Devices Market Landscape Analysis, 2016-2024
  • TABLE 25 North America Pricing Analysis
  • TABLE 26 North America Pricing Analysis (OPP, IPP, and RAP- 2016)
  • TABLE 27 U.S. Pricing Analysis-2016
  • TABLE 28 Canada Pricing Analysis-2016
  • TABLE 29 Europe Pricing Analysis (OPP, IPP, and RAP- 2016)
  • TABLE 30 U.K Pricing Analysis-2016
  • TABLE 31 Germany Pricing Analysis-2016
  • TABLE 32 France Pricing Analysis-2016
  • TABLE 33 Italy Pricing Analysis-2016
  • TABLE 34 Spain Pricing Analysis-2016
  • TABLE 35 Latin America Pricing Analysis (OPP, IPP, and RAP- 2016)
  • TABLE 36 Brazil Pricing Analysis-2016
  • TABLE 37 Mexico Pricing Analysis-2016
  • TABLE 38 Colombia Pricing Analysis-2016
  • TABLE 39 Asia Pacific Pricing Analysis (OPP, IPP, and RAP- 2016)
  • TABLE 40 Japan Pricing Analysis-2016
  • TABLE 41 China Pricing Analysis-2016
  • TABLE 42 India Pricing Analysis-2016
  • TABLE 43 Middle East Pricing Analysis (OPP, IPP, and RAP- 2016)
  • TABLE 44 Saudi Arabia Pricing Analysis-2016
  • TABLE 45 South Africa Pricing Analysis-2016
  List of Figures  
  • 1 Insulin Delivery Devices Market Segmentation
  • 2 Market Size & Growth Prospects
  • 3 Leading Brand Dynamics
  • 4 Penetration & Growth Prospects
  • 5 Industry Analysis – Porter’s
  • 6 Insulin Delivery Devices Market – PESTEL Analysis
  • 7 Insulin Delivery Devices Market Share by Product Type, 2016 & 2024
  • 8 Insulin Delivery Devices Market Share by Technology Type, 2016 & 2024
  • 9 Insulin Delivery Devices Market Share by Application Type, 2016 & 2024
  • 10 Insulin Delivery Devices Market Share by Region, 2016 & 2024

Key Insights Addressed:  

  • Defining market size from 2014 to 2016.
  • Estimating market growth till 2024 and consequence market forecast.
  • Identifying market drivers, restraints & future opportunities and allowing decision-maker with a range of possible outcomes and the probabilities that will occur for any choice of action.
  • Market segments and regions that will drive or lead market growth.
  • Defining Optimal Price Point (OPP) which will be accepted and recommended by maximum customers.
  • A bird’s-eye view of the competitive landscape and the key market players.
  • Key strategic growth driver adopted by market players. In-depth analysis of their strategies and implication on competition & growth.
    Key Findings:    
  • The global insulin delivery devices market was valued at $10.4 bn in 2016 and is anticipated to reach over $18.3bn by 2024.
  • The WHO (World Health Organization) estimates that in 2014, nearly 1.9 billion (39% of adults) aged 18 years and above were overweight, and out of these, 600 million (13% adults) were obese.
  • The geographical and demographic shift in the prevalence of diabetes is evident as 75% of adults with diabetes are present in low-income, middle-income countries.
  • The insulin pens are available in the price range of USD 300 to USD 700, whereas the other products are available at a much lower cost.
  • The insulin delivery devices market is dominated by players such as Novo Nordisk A/S, Eli Lilly, Becton, Dickinson and Company; Medtronic, Abbott, F. Hoffmann-La Roche Ltd, Mylan, Biocon and others.

Ameri Research implies a unique methodology of published information and primary research to bring key insights to customer decision making process. Our analytics model helps us to understand the structured and unstructured information from various sources. Key steps involves in the process are as below-

  1. Analyzing Published Information- Access to large pool of paid and unpaid published information via different sources and analyzing market trend.
  2. Setting Foundation- Input from analysis of secondary sources set our foundation to market analysis and helps in setting the scope for further research. Setting the scope involves Ameri Research proprietary statistical model, discussion with industry leaders, internal brainstorming, key discussion pointers from various forums etc.
  3. Need Gap Analysis- Defining the gap between our scope and availability of information.
  4. KOL Panel Discussion- Focused Group Discussion with a structured discussion guide to fine tune the gap and deriving the factors driving/restraining the market trend.
  5. Quantitative Research- Sampling large number of industry players, Education/Research Institutes, Government bodies, NGOs, Individual acclaimed researchers and conducting the primary interview with a structured questionnaire.
  6. Data Triangulation- We apply bottom-up demand approach or top-down estimation or a combined approach to triangulate the data points.
  7. Analyst Comment- Each of our analysts carries large pool of experience from domain perspective and add their value which is directional in nature
global-aesthetic-dermatology-market

To request a free sample copy of this report, please complete the form below verified and secure

We offer complete free customization that addresses client’s need. This includes insights from primary market research and a 60-minute free analyst consultation post report purchase.

This website is secure and your personal details are safe. Privacy policy

Description

The global insulin delivery devices market was valued at $10.4 bn in 2016 and is anticipated to reach over $18.3bn by 2024.

 

The insulin delivery devices market is anticipated to witness lucrative growth owing to the rise in prevalence of obesity, diabetes, growing geriatric population and changes in lifestyle. The lifestyle factors such as lack of physical activity, smoking, substance abuse, alcohol, and constant stress are strongly contributing to the early onset of diabetes and thus patients are now using diabetic management products for a significantly longer period.

 

The WHO (World Health Organization) estimates that in 2014, nearly 1.9 billion (39% of adults) aged 18 years and above were overweight, and out of these, 600 million (13% adults) were obese. The International Diabetes Federation (IDF), estimates that in 2015, over 400 million adults had diabetes and by 2040, it is estimated that over 642 million adults will be impacted due to the disease. The geographical and demographic shift in the prevalence of diabetes is evident as 75% of adults with diabetes are present in low-income, middle-income countries. The significant rise in prevalence of diabetes and obesity is anticipated to propel the usage of various insulin delivery devices over the forecast period.

 

The rise in geriatric population is amongst the key factors propelling the demand for insulin delivery devices. The IDF data suggest that majority of the diabetic population is in the age group of 40 years to 59 years. Moreover, 46% of the people with diabetes are undiagnosed and in 2015, and nearly 5 million deaths are attributed to the condition. In the U.S., as per the Administration of Aging (AoA) estimates, there are over 46.2 million people aged 65 and above and by 2040, this population is expected to increase by 21.7%. The significant rise in the aging population is anticipated to reinforce growth over the next few years strongly.

 

Insulin Delivery Devices Market 2024

 

Pricing Analysis

 

“Optimal Price Point (OPP) for Products”

 

Estimated Average insulin delivery device cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model. The average cost of insulin pumps is in the range of USD 4500 to USD 6000, and therefore are unaffordable to a large section of the population in living in the low and middle-income countries. The insulin pens are available in the price range of USD 300 to USD 700, whereas the other products are available at a much lower cost. Moreover, the technological advancements and rise in diabetic population, growing healthcare expenditure are improving access to quality healthcare and drive the market growth over the forecast period.

 

Insulin Delivery Devices Market by “Product”

 

The key products analyzed in the study include insulin pumps, syringes, needles, and injections. In 2016, insulin pens accounted for the largest share of over 39% owing to their wide usage portability, and convenience for use at any external location away from home. Some of the notable insulin products include Apidra, Victoza, Humalog, NovoLog, NovoPen, Autopen and others. Due to the rise in disease prevalence and healthcare expenditure, the demand for insulin products is expected to witness significant growth over the next few years. Moreover, the growing use of insulin injections and syringes is expected to create a niche market with low pricing and high volumes.

 

 

Insulin Delivery Devices Market by “End-Use”

 

Based on end-use, the market is segmented as hospitals, home healthcare and others. The home healthcare contributed the maximum revenue in 2016 and is expected to continue its lead over the forecast period. The growing awareness about diabetes management in home care settings using the portable injections, pumps, pens and other products is a key factor driving the market growth. Moreover, the significant cost and time saved by avoiding hospital visits are encouraging more patients to opt for home care treatment.

 

Europe Insulin Deliver Devices Market

 

Regional Segmentation

 

In 2016, North America was the leading region with a market share of nearly 39.5%, due to the high disease burden, presence of robust reimbursement framework, rising awareness about technologically advanced products, and patient safety features. The high healthcare expenditure in the U.S., the presence of global R&D headquarters, and streamlined clinical trial and product approval process of the U.S. FDA enables the introduction of several new products and technologies each year are some of the additional factors contributing to the high share of the region.

 

Asia Pacific is anticipated to register the highest CAGR of over 8.4% through the forecast period. The countries such as India and China now have the maximum number of people with obesity, lifestyle disorders, and diabetes. The IDF data suggests that the six South East Asian nations including India, Bangladesh, Nepal, Sri Lanka, Maldives and Mauritius collectively account for 78 million patients. Moreover, India is the diabetic capital of the world with 69.2 million patients living with diabetes. The high unmet needs, rising healthcare expenditure to improve healthcare access, awareness about genetic factors, lifestyle factors, physical health, and other nutritional factors is anticipated to propel market growth over the next few years.

.

“Competitive Landscape” and “Merger & Acquisition Insights”

 

The insulin delivery devices market is dominated by players such as Novo Nordisk A/S, Eli Lilly, Becton, Dickinson and Company; Medtronic, Abbott, F. Hoffmann-La Roche Ltd, Mylan, Biocon and others. The market is highly competitive and companies are looking out to acquire suitable assets and extend their dominance. Moreover, the high R&D investment for diabetes management is driving innovation and use of modern technology. For instance, the development of wearable insulin pump patch is anticipated to generate significant revenue over the next few years.

 

Market Segmentation

 

Insulin Delivery Devices Market by Product (Revenue, Million, 2014 – 2024)

  • Insulin Syringes
  • Insulin Pens
  • Insulin Pumps
  • Insulin Injectors

Insulin Delivery Devices Market by End-Use, (Revenue, USD Million, 2014 – 2024)

  • Hospitals
  • Homecare
  • Others

Insulin Delivery Devices Market Regional Outlook (Revenue, USD Million, 20124- 2024)

North America

  • U.S.
  • Canada

Europe

  • UK
  • Germany
  • France
  • Italy
  • Spain

Asia Pacific

  • Japan
  • China
  • India

Latin America

  • Brazil
  • Mexico
  • Columbia

Middle East and Africa

  • South Africa
  • Saudi Arabia

Additional information

Price

Single User $3,650, Multiple User $4,650, Enterprise User $6,650